Picture EBD Group World of Partnering Opportunities 650x100px

Document › Details

Bayer AG. (7/21/17). "Press Release: Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma [Not intended for U.S. and UK Media]". Berlin.

	Organisation	Bayer AG
	Group	Bayer (Group)
	Organisation 2	MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
	Group	MorphoSys (Group)
	Product	anetumab ravtansine (BAY 94-9343)
	Product 2	clinical research
	Person	LaCaze, Robert (Bayer 201702–202202 EVP of new Oncology Strategic Business Unit joined 2015 from BMS LEFT 2/22)

Original document
accessed by [iito] on 2017-07-24

Record changed: 2023-06-05

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Bayer (Group)

[1] Aignostics GmbH. (3/14/24). "Press Release: Bayer and Aignostics to Collaborate on Next Generation Precision Oncology"....
[2] BenevolentAI Ltd.. (1/24/24). "Press Release: BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer". London....
[3] Bayer AG. (10/10/23). "Press Release: Bayer Invests 250 million USD in New Cell Therapy Manufacturing Facility in the U.S. [Not intended for US and UK Media]". Berlin....
[4] Twist Bioscience Corporation. (10/5/23). "Press Release: Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million". Hamburg & Singapore....
[5] Bayer AG. (9/21/23). "Press Release: Bayer to Collaborate with Hologic in Breast cancer Imaging [Not intended for U.S. and UK Media]". Berlin....
[6] Bayer AG. (8/30/23). "Press Release: Strong Commitment to Modern Crop Protection Made in Europe. Bayer to Invest EUR 220 Million in New R&D Facility at Its Monheim Site". Monheim....
[7] Bayer AG. (8/29/23). "Press Release: Gene Editing – Pairwise and Bayer Start New Five-year Multi-million Dollar Collaboration to Further Advance Short-stature Corn". Durham, NC & Monheim....
[8] BlueRock Therapeutics LP. (8/23/23). "Press Release: BlueRock’s Phase I Study with Bemdaneprocel in Patients with Parkinson’s Disease Meets Primary Endpoint". Wuppertal....
[9] Bayer AG. (8/22/23). "Press Release: Bayer Appoints Dr. Juergen Eckhardt as New Head of Pharmaceuticals Business Development & Licensing / Open Innovation". Berlin....
[10] Lena Biosciences, Inc.. (8/7/23). "Press Release: Lena Biosciences Appoints Dr. Eckhard von Keutz to Its Business Advisory Board and Science Advisory Board"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]